Monogram Biosciences

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monogram Biosciences, Inc.
FormerlyViroLogic Inc.
Company typeSubsidiary
Nasdaq: MGRM
IndustryBiotechnology
HeadquartersSouth San Francisco, California
ProductsPhenoSense, PhenoSense GT, Trofile, GeneSeq, VeraTag, HERmark
Number of employees
379 (2008)
ParentLabCorp
Websitewww.monogrambio.com
Footnotes / references
[1]

Monogram Biosciences, Inc. (formerly ViroLogic Inc.) is an international biotechnology laboratory located in South San Francisco, California, USA and is a subsidiary of LabCorp. Monogram develops and markets assays to help guide and improve the treatment of infectious diseases (including HIV and Hepatitis) and cancer.

Virologic was founded in 1996 by Daniel Capon, Ph.D., Martin Goldstein and Robert S. Capon. The company went public (NASDAQ: VLGC) in 2000.[2]

Monogram was acquired by Laboratory Corporation of America in June 2009.[3]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
[edit | edit source]
  • Official website
  • Baseline HIV Type 1 Coreceptor Tropism Predicts Disease Progression [1]
  • Four Studies Affirm Significance Of Monogram's Trofile(TM) HIV Co-Receptor Tropism Assay [2]
  • Accuracy of Monogram's Trofile Assay in Determining Tropism and New Tropism Assays in Development [3]
  • Trofile Bests SensiTrop as Most Reliable Tropism Test [4]
  • Monogram Biosciences teams up with Pfizer for HIV treatment [5]
  • Monogram Biosciences Launches New "Trofile" HIV Co-receptor Tropism Test to Select Patients Eligible to User CCR5 Antagonist Maraviroc (Selzentry) [6]